Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

FDA finalizes new heart warnings | The impact of anti-DEI policies | Heart attack deaths are down | AI restores subpar MRI scans

News You Need to Know Today
FDA finalizes new heart warnings | The impact of anti-DEI policies | Heart attack deaths are down | AI restores subpar MRI scans
Friday, June 27, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

FDA finalizes new heart warnings for COVID-19 vaccines

The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines.

READ MORE >
COVID-19 vaccines help reduce the serious coronavirus infections and hospitalizations. Multiple studies have shown that the risk from very rare vaccine side effects are far outweighed by the much greater risk of hospitalization and death due to COVID infections.
Share on Twitter Share on Facebook Share on Linkedin

FDA finalizes new heart warnings for COVID-19 vaccines

Share on Twitter Share on Facebook Share on Linkedin
COVID-19 vaccines help reduce the serious coronavirus infections and hospitalizations. Multiple studies have shown that the risk from very rare vaccine side effects are far outweighed by the much greater risk of hospitalization and death due to COVID infections.
The new warnings, first proposed to Pfizer and Moderna in April, are now officially required by the FDA. They provide additional information about the potential risks of myocarditis and/or pericarditis associated with these vaccines.
READ MORE >

How anti-DEI healthcare policies are impacting patient care

All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.

READ MORE >
The first Black American College of Cardiology (ACC) president Kim Allan Williams, Sr., MD, MACC, MASNC, FAHA, FESC, chair, department of medicine, University of Louisville School of Medicine, explains the impact of Trump administration restrictions on diversity equity and inclusion (DEI) on healthcare programs and clinical trials that address women, minority and low-income patients.
Share on Twitter Share on Facebook Share on Linkedin

How anti-DEI healthcare policies are impacting patient care

Share on Twitter Share on Facebook Share on Linkedin
The first Black American College of Cardiology (ACC) president Kim Allan Williams, Sr., MD, MACC, MASNC, FAHA, FESC, chair, department of medicine, University of Louisville School of Medicine, explains the impact of Trump administration restrictions on diversity equity and inclusion (DEI) on healthcare programs and clinical trials that address women, minority and low-income patients.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
READ MORE >

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.

READ MORE >
cardiovascular heart diagnostics
Share on Twitter Share on Facebook Share on Linkedin

Heart attack deaths are way down after decades of breakthroughs—but other risks have skyrocketed

Share on Twitter Share on Facebook Share on Linkedin
cardiovascular heart diagnostics
Researchers explored more than 52 years of data, highlighting several key trends in the Journal of the American Heart Association.
READ MORE >

AI turns low-quality MRI scans into helpful heart images

A team of biomedical engineers, radiologists and cardiologists has developed a new AI model capable of restoring low-quality cardiac MRI scans.

READ MORE >
heart data research doctor cardiologist AI
Share on Twitter Share on Facebook Share on Linkedin

AI turns low-quality MRI scans into helpful heart images

Share on Twitter Share on Facebook Share on Linkedin
heart data research doctor cardiologist AI
A team of biomedical engineers, radiologists and cardiologists has developed a new AI model capable of restoring low-quality cardiac MRI scans.
READ MORE >

Featured Articles

TTVR with Evoque system linked to positive real-world outcomes after 30 days

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation. 

READ MORE >
The Evoque transcatheter tricuspid valve replacement (TTVR) system for tricuspid regurgitation from Edwards Lifesciences. The Evoque is the first transcatheter tricuspid valve approved by the FDA. It is the first TTVR cleared in the U.S.
Share on Twitter Share on Facebook Share on Linkedin

TTVR with Evoque system linked to positive real-world outcomes after 30 days

Share on Twitter Share on Facebook Share on Linkedin
The Evoque transcatheter tricuspid valve replacement (TTVR) system for tricuspid regurgitation from Edwards Lifesciences. The Evoque is the first transcatheter tricuspid valve approved by the FDA. It is the first TTVR cleared in the U.S.
According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation. 
READ MORE >

New report raises questions about data that helped heart drug gain FDA approval

Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.

READ MORE >
pharmaceutical drug approval process
Share on Twitter Share on Facebook Share on Linkedin

New report raises questions about data that helped heart drug gain FDA approval

Share on Twitter Share on Facebook Share on Linkedin
pharmaceutical drug approval process
Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.
READ MORE >

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

READ MORE >
Semaglutide (Wegovy) injector pen. Photo by Dave Fornell
Share on Twitter Share on Facebook Share on Linkedin

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

Share on Twitter Share on Facebook Share on Linkedin
Semaglutide (Wegovy) injector pen. Photo by Dave Fornell
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
READ MORE >

In Case You Missed It

GE HealthCare recalls legacy cardiology information systems due to security risk

GE HealthCare has warned that the devices could potentially be accessed and manipulated by an outside party. The FDA has classified this as a Class II recall. 

READ MORE >
the words "FDA recall" on a board
Share on Twitter Share on Facebook Share on Linkedin

GE HealthCare recalls legacy cardiology information systems due to security risk

Share on Twitter Share on Facebook Share on Linkedin
the words "FDA recall" on a board
GE HealthCare has warned that the devices could potentially be accessed and manipulated by an outside party. The FDA has classified this as a Class II recall. 
READ MORE >

AMA to advocate for improved Medicare payments for office-based labs

SCAI and other healthcare groups want changes made to how healthcare providers are paid after performing office-based lab procedures. "As much as we love delivering care as doctors, if we are losing money doing something, we cannot sustain it," one cardiologist explained. 

READ MORE >
SCAI AMA HOD delegates Jeff Marshall, MD, and And Edward Tuohy, MD, explain how the resolution will have AMA advocate for Medicare payment policy that removes high-ticket supplies from OBL physician payments and will enable these to be billed separately.
Share on Twitter Share on Facebook Share on Linkedin

AMA to advocate for improved Medicare payments for office-based labs

Share on Twitter Share on Facebook Share on Linkedin
SCAI AMA HOD delegates Jeff Marshall, MD, and And Edward Tuohy, MD, explain how the resolution will have AMA advocate for Medicare payment policy that removes high-ticket supplies from OBL physician payments and will enable these to be billed separately.
SCAI and other healthcare groups want changes made to how healthcare providers are paid after performing office-based lab procedures. "As much as we love delivering care as doctors, if we are losing money doing something, we cannot sustain it," one cardiologist explained. 
READ MORE >

Meditation linked to ‘real, lasting benefits’ for high-risk heart patients

A popular meditation technique may help high-risk patients protect their hearts for up to 10 years, according to a new randomized controlled trial published in Frontiers in Medicine.

READ MORE >
meditation yoga relax
Share on Twitter Share on Facebook Share on Linkedin

Meditation linked to ‘real, lasting benefits’ for high-risk heart patients

Share on Twitter Share on Facebook Share on Linkedin
meditation yoga relax
A popular meditation technique may help high-risk patients protect their hearts for up to 10 years, according to a new randomized controlled trial published in Frontiers in Medicine.
READ MORE >

In Other News

New AI-enabled, helium-free MRI system earns FDA clearance

The scanner requires just 0.7 liters of liquid helium for cooling—a fraction of the more than 1,500 liters standard systems need to operate safely. 

READ MORE >
Siemens Healthineers 1.5T helium-free MRI scanner
Share on Twitter Share on Facebook Share on Linkedin

New AI-enabled, helium-free MRI system earns FDA clearance

Share on Twitter Share on Facebook Share on Linkedin
Siemens Healthineers 1.5T helium-free MRI scanner
The scanner requires just 0.7 liters of liquid helium for cooling—a fraction of the more than 1,500 liters standard systems need to operate safely. 
READ MORE >

All 50 states agree to $7.4B opioid crisis settlement

The legal case brought by all 50 states, Washington D.C., and multiple U.S. territories against Purdue Pharma and the Sackler family has come to an end, with settlement funds set to be used for addiction recovery.

READ MORE >
Drugs money scam
Share on Twitter Share on Facebook Share on Linkedin

All 50 states agree to $7.4B opioid crisis settlement

Share on Twitter Share on Facebook Share on Linkedin
Drugs money scam
The legal case brought by all 50 states, Washington D.C., and multiple U.S. territories against Purdue Pharma and the Sackler family has come to an end, with settlement funds set to be used for addiction recovery.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Supreme Court sides supports cardiac drug maker | X-ray assesses pulmonary valve regurgitation | Making cardiac data actionable
Week in Review: Former ACC president dies | Administration questions vascular care | Is coffee bad for the heart | FFR-CT guide
New-look pacemaker uses ultrasound to stimulate the heart | Heartflow reports significant revenue growth | CCTA & CTO PCI
New FFR-CT standardization consensus document | FDA clears first tricupid surgical valve | ECG AI to detect amyloidosis
Shockwave Medical's new IVL catheter | BATMAN to the rescue | Antiplatelet drugs after PCI | FDA announces recalls
When TAVR patients require surgery later in life | Colleagues pay tribute to a cardiology powerhouse | Much more
TAVR Highlights: Self-expanding valves continue to impress | A new technique | Why implant depth matters | SAPT vs. DAPT

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup